Journal
LIVER INTERNATIONAL
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/liv.15777
Keywords
hepatitis B; hepatitis B immunoglobulin; hepatitis delta; liver transplantation
Categories
Ask authors/readers for more resources
This study analysed the real-life clinical practice of HBIG usage in HDV-related liver transplant patients and found that limited use of HBIG can effectively prevent HBV/HDV recurrence, especially when high-barrier NAs are used.
Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available